title: Control of junB and extracellular matrix protein expression by transforming growth factor-beta 1 is independent of simian virus 40 T antigen-sensitive growth-sensitive growth-inhibitory events.
abstract: Treatment of Mv1Lu mink lung epithelial cells with transforming growth factor-beta 1 (TGF-beta 1) prevents phosphorylation of the retinoblastoma susceptibility gene product, RB, in late G1 phase of the cell cycle, which is thought to retain RB in a growth-suppressive state. This effect is paralleled by cell cycle arrest in late G1 (M. Laiho, J. A. DeCapric, J. W. Ludlow, D. M. Livingston, and J. Massagué, Cell 62:175-185, 1990). Arrest can be prevented by expression of simian virus 40 T antigen, which binds to underphosphorylated RB, presumably blocking its growth-suppressive activity. The response of cells to TGF-beta 1, however, is complex and includes changes in the levels of expression of genes encoding nuclear transcription factors and extracellular matrix components. To define the relationships among various components of the TGF-beta 1 response, we have investigated the effect of TGF-beta 1 on cells whose growth-inhibitory response to this factor is prevented by T antigen. TGF-beta 1 addition to exponentially growing Mv1Lu cells increased the levels of junB mRNA and of three extracellular matrix proteins: plasminogen activator inhibitor-1, fibronectin, and thrombospondin. Kinetically, the effects on junB and plasminogen activator inhibitor-1 expression occurred faster (half-maximal at 1 to 2 h) than the effects on fibronectin and thrombospondin expression (half-maximal at 6 to 10 h). These effects either preceded or overlapped, respectively, the withdrawal of Mv1Lu cells from the cell cycle. Expression of a transfected T-antigen gene in Mv1Lu cells, however, did not prevent any of these responses to TGF-beta 1. The results indcate that TGF-B1-stimulated expression of junB and extracellular matrix proteins in Mv1Lu cells can occur independently of the T-antigen-sensitive events that lead to growth arrest.
authors.affiliation: Howard Hughes Medical Institute, Memorial Sloan-Kettering Cancer Center, New York, New York 10021.
authors.forename: M
authors.initials: M
authors.lastname: Laiho
authors.forename: L
authors.initials: L
authors.lastname: Rönnstrand
authors.forename: J
authors.initials: J
authors.lastname: Heino
authors.forename: J A
authors.initials: JA
authors.lastname: Decaprio
authors.forename: J W
authors.initials: JW
authors.lastname: Ludlow
authors.forename: D M
authors.initials: DM
authors.lastname: Livingston
authors.forename: J
authors.initials: J
authors.lastname: Massagué
mesh_terms: D000818:Animals; D002453:Cell Cycle; D002460:Cell Line; D004268:DNA-Binding Proteins / Q000235:genetics*; D005109:Extracellular Matrix / Q000378:metabolism*; D005353:Fibronectins / Q000235:genetics*; D005786:Gene Expression Regulation; D016161:Genes, Retinoblastoma / Q000187:drug effects; D008168:Lung; D008907:Mink; D015849:Plasminogen Inactivators / Q000378:metabolism*; D010980:Platelet Membrane Glycoproteins / Q000235:genetics*; D016755:Proto-Oncogene Proteins c-jun; D012333:RNA, Messenger / Q000235:genetics / Q000302:isolation & purification; D019699:Thrombospondins; D014162:Transfection; D016212:Transforming Growth Factor beta / Q000494:pharmacology*
chemical_list: D004268:DNA-Binding Proteins; D005353:Fibronectins; D015849:Plasminogen Inactivators; D010980:Platelet Membrane Glycoproteins; D016755:Proto-Oncogene Proteins c-jun; D012333:RNA, Messenger; D019699:Thrombospondins; D016212:Transforming Growth Factor beta